BUZZ-与 Halozyme 合作开发肥胖症药物,Skye 生物科学公司业绩攀升

路透中文
Jan 05
BUZZ-与 Halozyme 合作开发肥胖症药物,Skye 生物科学公司业绩攀升

1月5日 - ** 药物开发商Skye Bioscience SKYE.O股价盘前上涨4.76%至0.92美元

** 该公司称已与Halozyme Therapeutics HALO.O签署了一项全球协议,开发一种新的肥胖症治疗方法并可能将其商业化

** SKYE称将开发肥胖症实验药物尼马单抗的注射剂型

** 尼马单抗旨在帮助减肥;研究将测试与已用于治疗肥胖症的 GLP-1 药物的组合 - SKYE

** 公司计划在 2026 年中期进行新制剂的中期试验

** 如果药物获得批准并上市,Halozyme 公司将获得里程碑付款和版税 - 天际网

** 截至上次收盘,股价在过去一年中上涨了约 17

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10